Business Context and Reporting Period
Neurosense Therapeutics Ltd., a foreign private issuer based in Herzliya, Israel, filed Form 6-K for the month of June 2026. The filing, dated June 9, 2026, serves to report a specific corporate event rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an event-driven report and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the receipt of a Japanese patent grant for the company's "PrimeC Novel Composition." This intellectual property milestone was announced via a press release issued on June 9, 2026.
Guidance, Outlook, and Risks
The filing incorporates the first two paragraphs of the June 9, 2026 press release into the company's existing Registration Statements on Form S-8 and Form F-3. No specific financial guidance, management outlook, risk factors, or contingencies are detailed within the text of this specific Form 6-K.
Investor Verification Points
- Verify the scope and commercial implications of the Japanese patent grant for the PrimeC Novel Composition.
- Review the full text of the press release (Exhibit 99.1) for details on the patent's validity period and territorial coverage.
- Confirm the status of the PrimeC development pipeline in relation to this new intellectual property protection.